The effect of captopril on definitive patients with coronavirus pneumonia

Phase 2

Recruiting

• Conditions: Coronavirus pneumonia.; This code assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing; U07.1

• Registration Number: IRCT20140824018915N10
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

COVID-19 disease confirmed by imaging (HRCT) or Real Time PCR

Exclusion Criteria

Pregnancy
Breastfeeding
Bilateral renal artery stenosis
Hereditary angioedema
Psoriasis
NSAID consumtion
Patients who have been taking Captopril before undergoing Covid due to other underlying diseases (such as hypertension, heart failure, myocardial infarction, etc.) will not be included in the study.
Patients in need of ICU admission
The patient participates in any other clinical trial on the corpus associated with therapeutic intervention. (Before entering this study)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of oxygen secretion. Timepoint: At the beginning of the study (before the intervention) and 14 days after the start of taking captopril. Method of measurement: Using a pulse oximeter.;Mortality rate. Timepoint: At the end of hospitalization of patients. Method of measurement: According to the physician report.;Duration of hospitalization. Timepoint: At the end of hospitalization of patients. Method of measurement: According to the physician report.